Physician profile
Frederick C Delafield
NPI 1982708939
$1,246.69
in general payments reported to CMS, 2019-2025
10 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $306 · 2020: $129 · 2021: $14.29 · 2022: $362 · 2023: $49.46 · 2024: $270 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $435.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $434.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $329.63 | 2019-2025 | Jardiance |
| Inari Medical, INC. | $201.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $197.73 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $159.45 | 2019-2024 | Xarelto |
| Dexcom, INC. | $140.84 | 2022 | |
| Pfizer INC. | $130.16 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $29.93 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.83 | 2019 | |
| Alexion Pharmaceuticals, INC. | $21.61 | 2019 | |
| Lilly USA, LLC | $11.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frederick Delafield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.